BIOLINERX     Print Page  Close Window

SEC filings
6-K
BIOLINERX LTD. filed this Form 6-K on 08/11/2016
Entire Document
 

 
BioLineRx Ltd.
APPENDIX TO CONDENSED CONSOLIDATED INTERIM CASH FLOW STATEMENTS
(UNAUDITED)

   
Six months ended June 30,
 
   
2015
   
2016
 
   
in USD thousands
 
             
Adjustments required to reflect net cash used in operating activities:
           
             
Income and expenses not involving cash flows:
           
Depreciation and amortization
   
195
     
245
 
Long-term prepaid expenses
   
(8
)
   
4
 
Interest and exchange rate differences on short-term deposits
   
(49
)
   
(204
)
Share-based compensation
   
487
     
582
 
Exchange differences on cash and cash equivalents
   
13
     
(42
)
Loss (gain) on adjustment of warrants to fair value
   
887
     
(193
)
     
1,525
     
392
 
                 
Changes in operating asset and liability items:
               
Increase in prepaid expenses and other receivables
   
(425
)
   
(352
)
Increase (decrease) in accounts payable and accruals
   
876
     
(263
)
     
451
     
(615
)
     
1,976
     
(223
)
                 
Supplementary information on investing activities not involving cash flows:
               
    Property and equipment acquired on supplier trade credit
   
512
     
-
 
                 
Supplementary information on interest received in cash
   
30
     
192
 
 
The accompanying notes are an integral part of the financial statements.

10